Floatz logo

Recombinant Human Thrombopoietin

Thrombocytopenia

Sun Yat-sen Universityprotein_peptidePhase 4 / ApprovedActive
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Thrombocytopenia cohort.

Asset / SponsorPhaseRating
sb-497115-gr
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
Avatrombopag
Second Affiliated Hospital of Guangzhou Medical University
Phase 4BB
FILGRASTIM
OHSU Knight Cancer Institute
Phase 2BB
Hetrombopag
Sun Yat-sen University
Phase 3BB
Cytosin-Arabinosid
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Recombinant Human Thrombopoietin is also rated in:

chemotherapy-induced toxicityDormant
B
Indicative ·
60 / 100
View asset →
thrombocytopenia due to immune destructionDormant
B
Indicative ·
60 / 100
View asset →
colorectal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →